Compounds, showing selectivity towards COX-2, are
promising agents as selective non-steroidal anti-inflammatory drugs
(NSAIDs) with lower side effects, especially, gastrointestinal ones.
However, recent reports reveal the cardiovascular side effec
ts
associated with the selective COX-2 inhibitors. Therefore, attempts
have been done to develop the second generation of selective COX-2
inheritors. They have safer profile compared to the first generation.
Lumiracoxib belongs to this class of compounds. In this study, the
molecular structure of the target enzymes were prepared. Library of
rationally designed lumiracoxib analogues were docked.
Nowadays, glycogen synthase kinase 3 (GSK-3) inhibitors become
one of the most important drug targets for the development of their
selective inhibitors serving as promising drugs for the treatment of
many diseases, particularly Alzheimer's disease
. Targeting GSK-3
enzyme has a therapeutic importance in many diseases and is one of
the valuable fields for researchers in both academic research centers
and pharmaceutical companies.
The Reaction of Glycerol carried out with tow aryl halides
under basic conditions (K2CO3) using 5 mol% of Pd(II)Complex as
catalyst, Pd(PPh3)2Cl2. The typical reaction has been performed
between glycerol and bromobenzene. This reaction is achieved
in
water as solvent. However, the catalyst complex does not dissolve
in aqueous solutions rather it acts as heterogeneous catalyst.
Therefore, it is filtrated at the end of the reaction and reused several
times. Accordingly, new compound were prepared by reacting
glycerol with 1-bromo-2,6-dichlorobenzene. It is anticipated that the
synthesized compounds may have pharmaceutical application.
Phenol derivatives have been reacted with aryl halides under
heterogeneous basic catalyst (Amberlyst-21) using 5 mol% Cu(I)
Complex as catalyst, [CuClPPh3]4. The typical reaction has been
performed between p-cresol and bromobenzene. This reaction
is
achieved in o-xylene as solvent. However, the catalyst complex
does not dissolve in toluene rather it acts as heterogeneous catalyst.
Therefore, it is filtrated at the end of the reaction and reused several
times. Accordingly, new compounds were prepared by reacting one
of the bromoaryl derivatives with paracetamol. It is anticipated that
the synthesized compounds may have pharmaceutical application as
non-steroidial anti-inflammatory drugs (NSAIDs).
